Search

Rigel Pharmaceuticals Inc

Fechado

SetorSaúde

45.97 5.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

42.27

Máximo

43.47

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+53.12% upside

Dividendos

By Acuity

Próximos Ganhos

3 de nov. de 2026

Sentimento de Notícias

By Acuity

50%

50%

156 / 340 Ranking em Healthcare

Rigel Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de ago. de 2026, 22:01 UTC

Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.

17 de ago. de 2026, 20:06 UTC

News

Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.

14 de ago. de 2026, 20:06 UTC

Event
News

HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.

13 de ago. de 2026, 19:16 UTC

News
Event

Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.

11 de ago. de 2026, 20:06 UTC

Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.

7 de ago. de 2026, 19:26 UTC

News

Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.

6 de ago. de 2026, 20:06 UTC

News

Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.

5 de ago. de 2026, 20:02 UTC

News

Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.

4 de ago. de 2026, 23:01 UTC

News

Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.

3 de ago. de 2026, 19:26 UTC

Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.

31 de jul. de 2026, 19:41 UTC

Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.

30 de jul. de 2026, 19:29 UTC

Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.

29 de jul. de 2026, 19:47 UTC

Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.

28 de jul. de 2026, 19:56 UTC

News

Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.

27 de jul. de 2026, 16:16 UTC

Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.

24 de jul. de 2026, 20:01 UTC

Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.

22 de jul. de 2026, 20:06 UTC

Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.

21 de jul. de 2026, 17:26 UTC

News

Rigel Pharmaceuticals Inc shares are higher, reflecting positive sentiment in the biotechnology sector amid broader market gains, particularly in technology stocks.

Comparação entre Pares

Variação de preço

Rigel Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

53.12% parte superior

Previsão para 12 meses

Média 65 USD  53.12%

Máximo 85 USD

Mínimo 43 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Rigel Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

156 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

$

help-icon Live chat